CTOs on the Move

Q32 Bio

www.q32bio.com

 
Q32 Bio is a biotechnology company developing therapeutics targeting powerful regulators of the innate and adaptive immune systems, with the goal of re-balancing the immune system in severe autoimmune and inflammatory diseases. Focused on the IL-7 pathway and complement system, Q32 Bio is addressing dysregulation to help patients take back control of their lives in diseases with few to no treatment options, or those diseases where current therapeutics provide inadequate relief.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.q32bio.com
  • 830 Winter Street
    Waltham, MA USA 02451
  • Phone: 781.999.0232

Executives

Name Title Contact Details
Saul Fink
Chief Technology Officer Profile

Funding

Q32 Bio raised $46M on 05/27/2020
Q32 Bio raised $60M on 10/29/2020

Similar Companies

CepTor Corporation

CepTor Corporation is a Cockeysville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cadent Therapeutics

Cadent Therapeutics is a precision neuroscience company developing novel medicines that tune and modulate brain rhythms to restore cognitive and motor function in patients with serious neurological disease.

Pfenex

We are a clinical stage development and licensing biotechnology company focused on leveraging our Pfenex Expression Technology™ platform to develop and improve protein therapies for unmet patient needs.

Accelerated Technologies Partners

Accelerated Technologies Partners is a Hackensack, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BioMotiv

BioMotiv is an accelerator company associated with The Harrington Project, a $340 million initiative centered at University Hospitals of Cleveland.